Cochrane · systematic review · CD014089

Phosphodiesterase 5 inhibitors (PDE5i) for the treatment of Raynaud's phenomenon

Maltez, N, Maxwell, LJ, Rirash, F, et al. · Cochrane Database of Systematic Reviews · 2023 · Cochrane Library

SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.

Questions

current version

GRADE rated

No studies

Included studies

No studies 0 · 0%Ungraded 0 · 0%Very low 1 · 14.3%Low 4 · 57.1%Moderate 2 · 28.6%High 0 · 0%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Questions and results

Phosphodiesterase 5 inhibitors (PDE5i) compared to placebo in the treatment of Raynaud's phenomenon

Population: adults with Raynaud's phenomenon (primary or secondary)

7 questions

Outcome	Effect	Evidence	Status / GRADE
Frequency of attacks per week Phosphodiesterase 5 inhibitors (PDE5i) vs placebo	no estimate extracted	NR	Low Downgraded: imprecision, inconsistency
Duration of attacks per day (minutes) Phosphodiesterase 5 inhibitors (PDE5i) vs placebo	no estimate extracted	NR	Low Downgraded: imprecision, inconsistency
Severity of Raynaud's attack Phosphodiesterase 5 inhibitors (PDE5i) vs placebo	no estimate extracted	NR	Very low Downgraded: risk of bias, imprecision, publication bias
Pain intensity Phosphodiesterase 5 inhibitors (PDE5i) vs placebo	no estimate extracted	NR	Low Downgraded: imprecision, inconsistency
Patient global Phosphodiesterase 5 inhibitors (PDE5i) vs placebo	no estimate extracted	NR	Low Downgraded: imprecision
Withdrawals due to adverse events Phosphodiesterase 5 inhibitors (PDE5i) vs placebo	no estimate extracted	NR	Moderate Downgraded: imprecision
Serious adverse events Phosphodiesterase 5 inhibitors (PDE5i) vs placebo	no estimate extracted	NR	Moderate Downgraded: imprecision